Nexgel, INC 8-K filings

NexGel, Inc. reported that its 2026 Annual Meeting of Stockholders saw the rejection of several critical proposals, including reincorporation, an increase in authorized shares, and a reverse stock split.

NexGel, Inc. has entered into a new Executive Employment Agreement with CEO Adam Levy, detailing salary, bonus potential tied to EBITDA, and stock options.

NexGel, Inc. has postponed its 2026 Annual Meeting of Stockholders from July 10, 2026, to July 31, 2026, to allow more time for proxy solicitation.

NexGel, Inc. announced the resignation of director Scott Henry, effective July 1, 2026, citing a desire to reduce his workload and focus on other ventures.

NexGel, Inc. has released a new investor presentation dated June 2026, providing updated information to stakeholders.

NexGel, Inc. announced the appointment of Brian J. Kieser and Kevin Harris to its Board of Directors, coinciding with a strategic financing led by Sequence LifeScience.

NexGel, Inc. has appointed veteran financial leader Ian Blackman as Chief Financial Officer to oversee the integration of the Celularity acquisition and scale its healthcare and beauty portfolio.

NexGel, Inc. has received a formal deficiency notice from Nasdaq after its common stock failed to maintain a minimum bid price of $1.00 for 30 consecutive business days.

NexGel, Inc. has finalized its acquisition of Celularity's regenerative biomaterials portfolio, financed by a $5.5 million investment from Sequence LifeScience, aiming to triple revenue and enhance profitability.

NexGel, Inc. has secured $1.797 million in Series A convertible notes to fund a potential acquisition, with an additional $14.869 million contingent on the acquisition's closing and further capital up to $40 million available.

Nachum Stein has resigned from NexGel, Inc.'s Board of Directors and its Compensation Committee, effective February 2, 2026, citing a desire to lighten his schedule.

NEXGEL, Inc. announced the appointment of Adam E. Drapczuk III as Interim Chief Financial Officer, replacing Joseph F. McGuire, effective January 1, 2026.

NEXGEL announced the spin-off of its drug delivery program into NexGelRx, securing a 5% perpetual royalty and a 19.99% non-dilutive equity stake.

NEXGEL, Inc. has cancelled its Special Meeting of Stockholders, withdrawing a proposal to significantly increase its authorized common stock from 25 million to 1 billion shares.

NEXGEL, a hydrogel product provider, announced third quarter 2025 financial results, showing flat revenue but a sequential narrowing of its Adjusted EBITDA loss.

NEXGEL, Inc. reported a 100.3% increase in second quarter 2025 revenue to $2.88 million, significantly improving gross profit margins and reducing net and EBITDA losses.

NEXGEL, Inc. announced the appointment of Steven A. Ciardiello, Chief Accounting Officer for Shutterstock, Inc., to its Board of Directors and Audit Committee.

NEXGEL, Inc. announced a registered direct offering and concurrent private placement, raising approximately $1.055 million to strengthen its balance sheet and support anticipated growth.

NexGel, Inc. announced the adoption of a new investor presentation, effective July 31, 2025.

NEXGEL, Inc. announced an expanded partnership with STADA Arzneimittel AG, including new product launches in North America and a $1 million non-dilutive capital advance to support go-to-market strategies.

NEXGEL, Inc. announced that its stockholders approved all five proposals at the 2025 Annual Meeting, including an increase in shares for the long-term incentive plan, election of directors, and executive compensation matters.

NEXGEL, Inc. has filed a Form 8-K with the SEC, disclosing the adoption and utilization of a new investor presentation dated June 2025.

NEXGEL announces a significant revenue increase of 121% in Q1 2025, driven by growth in both contract manufacturing and branded products, alongside improved gross profit margins.

NEXGEL, Inc. released a new investor presentation on March 25, 2025, as disclosed in a Form 8-K filing.

NEXGEL announces record fourth quarter and full year 2024 financial results, with revenue growth exceeding 100% for the third consecutive year, and issues revenue guidance of $13 million for 2025 with expected positive EBITDA.

NEXGEL reports strong revenue growth in 2024 and anticipates positive cash flow in 2025.

NEXGEL, Inc. has appointed Joseph F. McGuire as Chief Financial Officer, effective January 1, 2025, and has entered into new employment agreements with both the CEO and CFO, including salary increases, stock options, and bonus opportunities.

NEXGEL announced record third-quarter revenue of $2.94 million, a 141% increase year-over-year and 104% sequentially, driven by growth in branded consumer products and contract manufacturing.

NexGel, Inc. has announced a registered direct offering expected to raise $2 million to support working capital, inventory, and potential acquisitions.

NEXGEL, Inc. has released a new investor presentation on October 28, 2024, to update stakeholders on the company's progress.